Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mallinckrodt PLC MCKPF

Mallinckrodt plc develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies. The Company operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The Company focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.


OTCPK:MCKPF - Post by User

Bullboard Posts
Next >>
Post by winterskyon Jul 06, 2017 11:09pm
302 Views
Post# 26443008

huge news this is big UMB

huge news this is big UMBThe expansion plan includes two buildings and four phases of construction. The first phase is a building envelope of 130,000 sq ft.  Second phase is the second level completion of equal square footage bringing the total of the first building to 260,000 sq ft. The second building, first floor phase three construction, is 80,000 sq ft. Fourth and final phase construction of the second level completes the 420,000 square foot expansion plans. Once the entire project is completed and licensed it has the potential to produce over 110,000 kg of cannabis per year or over $500 million annually.
Bullboard Posts
Next >>